Mizuho Securities Initiates Coverage on Relypsa Inc(NASDAQ:RLYP). The shares have been rated Neutral. The rating by Mizuho Securities was issued on Apr 12, 2016.
In a different note, Raymond James said it Initiates Coverage on Relypsa Inc, according to a research note issued on Apr 1, 2016. The shares have been rated ‘Market Perform’ by the firm. Brean Capital said it Initiates Coverage on Relypsa Inc, according to a research note issued on Mar 29, 2016. The shares have been rated ‘Buy’ by the firm. On Mar 16, 2016, Citigroup said it Maintains its rating on Relypsa Inc. In the research note, the firm Lowers the price-target to $38.00 per share. The shares have been rated ‘Buy’ by the firm. On Feb 25, 2016, Stifel Nicolaus said it Maintains its rating on Relypsa Inc. In the research note, the firm Lowers the price-target to $40.00 per share. The shares have been rated ‘Buy’ by the firm.
Relypsa Inc (RLYP) shares turned negative on Fridays trading session with the shares closing down -3.52 points or -15.94% at a volume of 72,87,247. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $21.49. The peak price level was also seen at $21.49 while the days lowest was $18.25. Finally the shares closed at $18.56. The 52-week high of the shares is $37.88 while the 52-week low is $10.26. According to the latest information available, the market cap of the company is $804 M.
Relypsa Inc(RLYP) last announced its earnings results on Feb 24, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $11.96M. Analysts had an estimated revenue of $7.37M. Earnings per share were $-1.40. Analysts had estimated an EPS of $-1.35.
Several Insider Transactions has been reported to the SEC. On Mar 16, 2016, Kristine M Ball (CFO) purchased 7,000 shares at $12.15 per share price.Also, On Mar 16, 2016, Thomas J. Schuetz (director) purchased 30,000 shares at $13.39 per share price.On Jan 4, 2016, Wilhelm Stahl (SVP, Chief Technology Officer) sold 20,000 shares at $28.53 per share price, according to the Form-4 filing with the securities and exchange commission.
Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.